{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Back Bay Life Science Report","title":"The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/82bc977f\"></iframe>","width":"100%","height":180,"duration":1483,"description":"A conversation on the rising trends in the cardiology space\nCardiology has historically been a cornerstone of large pharmaceutical portfolios. The late 2000s and 2010s saw many pharmaceutical companies and investors abandon or severely deprioritize cardiology research and development in favor of oncology, immunology, and neurology.\nDuring this episode of The Life Science Report, Dr. Pete Bak and Christian Thienel of Back Bay Life Science Advisors discuss the major players in the industry and novel approaches to future cardiology applications.\n\nEpisode topics include: \nWhy pharma’s interest in specialty-like approaches has shifted towards cardiology\nThe promise of “advanced modalities” and gene therapies, such as antisense oligonucleotides (ASOs) and small interfering RNA (siRNA)\nHow these newer treatments stack up against traditional small molecule orals, like statins\nClinical stage pipeline analysis across cardiology and visible trends on the horizon\nThis is the 20th episode of Back Bay’s podcast, covering all facets of healthcare development and transactions. For questions, be in touch: www.bblsa.com","thumbnail_url":"https://img.transistorcdn.com/W6Lngt-BhnFN8FVt3HSPeq-NUJHgo4jaJncMb2aU6_E/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS81NjE3/MTc3NDg3NzgyNTI0/ODE3Y2ViM2Q4OWI5/MDUzMC5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}